The global collective intelligence network aims to accelerate precision oncology research and care

BOSTON andROLLE,Switzerland,Sept. 12,2024 -- SOPHiA GENETICS (Nasdaq: SOPH),a cloud-native healthcare technology company and a global leader in data-driven medicine,today announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY is the global consortium announced at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutions to fuel the next wave of innovation in oncology by making real-world data available for research.

SOPHiA UNITY,the pioneering initiative by SOPHiA GENETICS,harnesses multimodal data and analytics to drive innovation from a global network. The bar for innovation in oncology is increasing as indications become more fragmented,more complex and requiring larger datasets. No single institution can address this challenge alone. SOPHiA GENETICS launched SOPHiA UNITY to meet this challenge,harmonizing high-quality,diverse,multimodal data at scale,leveraging the collective intelligence of leading research institutions.

Exactis Innovationin Montreal,Quebec,Canada,an organization of hospital partners dedicated to improving cancer survivorship through real-world data,as well as Institut Paoli-Calmettes in Marseille,France,one of the largest cancer centers in France,will be joining SOPHiA UNITY. In addition,Gemelli Hospital in Rome,Italy,named the best hospital in Italy in 2024,has expressed interest in joining the collaborative.

These organizations accompany inaugural member Memorial Sloan Kettering Cancer Center,a top cancer treatment and research institution. The SOPHiA UNITY network includes three countries and over 100,000 committed patient profiles with multimodal data.

"By uniting a critical mass of data and expertise through SOPHiA UNITY,we are empowering a global network of top-tier institutions to leverage real-world data to tackle the complexities of cancer. This initiative provides a new opportunity to advance oncology research with one of the most robust sources of diverse data available in the market to drive breakthroughs and improve patient outcomes worldwide," said Jurgi Camblong,PhD,Co-founder and CEO of SOPHiA GENETICS. "Together,we have the power to change the world."

Members benefit from participating in innovative global projects funded by industry and have access to the SOPHiA GENETICS AI-driven technology that increases efficiency of data curation,structuring and harmonization efforts. Collaborations made possible by SOPHiA UNITY pave the way for continued advancement of oncology research and data-driven medicine.

Members of SOPHiA UNITY can use SOPHiA CarePath™ which provides large-scale data insights from various modalities—including imaging,genomics,and pathology,as well as clinical notes and a diverse array of patient profiles. Data are safely and anonymously collected,harmonized and curated using SOPHiA GENETICS' advanced AI-based technology and proprietary algorithms,delivering meaningful,data-driven insights.

For more information visitSOPHiAGENETICS.COM,or connect onLinkedIn.

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™,a platform that analyzes complex genomic and multimodal data and generates real-time,actionable insights for a broad global network of hospital,laboratory,and biopharma institutions. For more information,visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and,if applicable,may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release,including statements regarding SOPHiA GENETICS future results of operations and financial position,business strategy,products and technology,partnerships and collaborations,as well as plans and objectives of management for future operations,are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to the company's management. Such statements are subject to risks and uncertainties,and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors,including those described in the company's filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company's expectations or any change in events,conditions,or circumstances on which such statements are based,unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.